Skip to main content
. 2022 Jun 10;11(12):3330. doi: 10.3390/jcm11123330

Figure 2.

Figure 2

Fluorescein uptake patterns based on pathology and Gadolinium (Gd)-enhancement. (A,B) Distribution of Fluorescein uptake and diagnostic yield based on pathology. (C,D) Fluorescein uptake and diagnostic yield depending on Gadolinium uptake on MRI. Samples were categorized in four categories: (1) fluorescein-positive and tumor/tissue diagnosis positive (F+T+), (2) fluorescein-positive and tumor/tissue diagnosis negative (F+T-), (3) fluorescein-negative and tumor/tissue diagnosis positive (F-T+), (4) fluorescein-negative and tumor/tissue diagnosis negative (F-T-). Abbreviations: DA II = diffuse astrocytoma; IDH-mutant WHO grade II; AA III = anaplastic astrocytoma; IDH-mutant WHO grade III; B-Cell NHL = B-cell non-Hodgkin lymphoma; GBM IV = glioblastoma WHO grade IV; Gd = gadolinium; MS = multiple sclerosis; OD II = oligodendroglioma; IDH-mutant and 1p/19q-codeleted WHO grade II; PTLD = post transplantation lymphoproliferative disorder.